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ABSTRACT 
Gliomas represent approximately 80% of all malignant brain tumors, and 
glioblastoma multiforme (GBM) accounts for nearly half of all gliomas. GBM is the most 
common and aggressive primary brain tumor. Despite aggressive treatment including 
tumor resection followed by radiation and chemotherapy, the median survival rate for GBM 
averages between 12 and 15 months, with a 2-year survival rate less than 25%. Therefore, 
new therapeutic strategies are needed to improve the survival rate of those affected by 
GBM. Chemotherapy with the DNA alkylating agent, Temozolomide (TMZ), is commonly 
used as a first-line treatment for GBM. TMZ is an orally delivered drug that is known to be 
stable or inactive in the acidic pH environment of the stomach and begins to convert to its 
active form at a neutral pH in the bloodstream. However, studies have shown that full 
conversion of TMZ to its active form occurs at a more basic pH. Further, after TMZ is 
converted to its active form, it is unable to cross the blood-brain barrier, thereby limiting 
availability in the brain and lowering the effectiveness of TMZ.  
Recently, peptides have been utilized as delivery systems for hydrophobic 
anticancer drugs or agents. These peptides are advantageous due to their 
biocompatibility, and high loading capacity for hydrophilic and hydrophobic drugs. To 
facilitate the delivery of TMZ, and potentially other hydrophobic drugs, we propose an 
innovative local delivery strategy using hydrophilic and alternating hydrophobic and acidic 
amino acids to form a peptide hydrogel. We hypothesize that the hydrophobic residues of 
the peptide hydrogel will load TMZ, and the hydrophilic residues will convert TMZ to its 
active form as the hydrogel degrades. This therapeutic strategy will allow for extended 
release of TMZ, thus increasing the efficacy of the drug.  
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In this study, peptide sequences were designed, synthesized, and formed into 
hydrogels for the delivery of TMZ. In vitro experiments validated that TMZ dissolved at a 
higher pH resulted in significantly increased cytotoxicity in LN-18 and T98G human 
glioblastoma cells. We also demonstrated that at various concentrations, the proposed 
peptide hydrogel efficiently loads TMZ and the release profiles can be adjusted based on 
peptide composition. Further, studies showed that TMZ-loaded peptide hydrogels 
mediated greater anticancer activity in LN-18 cells compared to delivery of TMZ alone. 
Overall, our results demonstrate the therapeutic potential of the TMZ-loaded peptide 
hydrogels for local drug delivery in treating GBM. 
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CHAPTER 1 
INTRODUCTION & BACKGROUND 
Each year an estimated over 25,000 adults and children in the United States will 
be diagnosed with cancerous tumors in the brain or spinal cord.1 The frequency of brain 
tumors increases with age, with the median age of diagnosis being 59,1 and an average 
incidence of 40.1 per 100,000 in those over 40.1 Brain tumors are also the most common 
cancer in children between the age of 0-14, and the third most common cancer-related 
death in people between the ages 15 and 39.1 
Of the many types of central nervous system and primary brain tumors, gliomas 
and meningiomas are the most common.2 Gliomas represent 24.7% of all primary brain 
tumors and other CNS tumors and 74.6% of malignant brain tumors.2 Gliomas are 
known to arise from supporting cells of the brain, such as astrocytes or 
oligodendrocytes, and are classified based on the malignancy grade. Grade I tumors are 
benign with an almost normal appearance, grade II is considered low-grade diffuse 
glioma, grade III is classified as malignant diffuse glioma, and grade IV is considered 
glioblastoma.2 The grades are assigned based on the presence/absence of necrosis, 
amount of proliferation, and mitotic activity.2 Glioblastoma multiforme (GBM) is the most 
common malignant brain tumor with an incidence of 5-8 people per 100,000, and overall 
accounting for 55.4% of gliomas1. With a median age of onset at 64, GBM follows the 
same trend as all cancerous brain tumors; the incidence rate increases with age, with 
the highest diagnoses rates occurring between ages 75-84 years old. The incidence of 
GBM is slightly higher in men than in women, and occurs more often in Caucasians 
compared to other ethnicities.3 The median survival rate for patients with GBM is 
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between 12 to 15 months,4 even with aggressive treatment involving surgery, 
chemotherapy, and radiation.4  
1.1 Current Treatment 
The current standard of care for treating GBM includes maximal surgical resection, 
followed by radiation, and then chemotherapy.3 However, complete resection of GBM 
tumors is difficult due to the invasive nature of the tumors and the areas of the brain in 
which they are located, which are usually responsible for controlling speech and motor 
function.3 The current standard treatment following surgical resection consists of 
radiotherapy plus concomitant chemotherapy with temozolomide (TMZ).3 TMZ is a 
prodrug that undergoes spontaneous hydrolysis at physiological pH to the active 
metabolite 3-methyl-(triazen-1-yl)imidazole-4-car-boxamide (MTIC).5 The drug further 
hydrolyzes into 5-amino-imidazole-4-carboxamide (AIC), providing the active alkylating 
or reactive portion of the drug needed to promote DNA methylation.5 TMZ primarily 
exerts its affect by methylation of guanine DNA at the O6 position, initiating a base pair 
mismatch, and ultimately leading to apoptosis.5 TMZ was approved for treatment of 
glioblastoma in 1999, and has a 96-100% bioavailability when delivered orally.6 Due to 
the pharmacokinetic properties of TMZ, only 30% of the drug has been found to reach 
the central nervous system.7 Despite this, studies have shown that patients receiving 
radiation therapy along with concomitant and adjuvant TMZ treatment was more 
effective than radiation alone.4 In one study, patients who received radiotherapy with 
TMZ had a median survival time of 14.6 months with a two-year survival rate of 27.2%, 
compared to 12.1 months and 10.9% of patients surviving two years that received 
radiotherapy alone.4 Since GBM is a highly vascularized tumor and is characterized by 
increased endothelial growth factor signaling, utilizing antiangiogenic therapeutic 
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strategies in addition to TMZ have been explored.6 Bevacizumab is a monoclonal 
antibody antiangiogenic therapy that was approved in 2009 for treatment of GBM. 
Bevacizumab binding to vascular endothelial growth factor (VEGF) prevents interaction 
with the VEGF receptor, resulting in a reduction of vascular growth within the tumor.8 
Clinical trials testing the combination of bevacizumab with TMZ and radiotherapy have 
reported improvement of progression-free survival in patients with GBM, but no gain in 
overall survival.9  
In addition, local delivery of an alkylating drug, bis-chloroethylnitrosourea (BCNU), 
has been explored using Gliadel wafers, a polymeric (poly carboxyphenoxy-
propane/sebacic acid anhydride) substrate that allows release of BCNU for 
approximately 3 weeks.6 Locally administered gliadel wafers allow for a reduction in 
systemic toxicity and a higher drug concentration at the tumor resection site.10 Gliadel 
wafers have been used as an adjuvant therapy in combination with systemic delivery of 
temozolomide, but the adjuvant therapy effectiveness was limited due to toxicity and 
small survival increase.6  
1.2 Barriers to Current Treatment 
Several barriers remain for providing effective drug treatment to patients with GBM; 
these include crossing the blood-brain barrier (BBB) and development of 
chemotherapeutic resistance.  
1.2.1 Blood Brain Barrier 
The blood-brain barrier (BBB) is composed of brain endothelial cells with tight 
junctions that allow diffusion of water and small lipophilic molecules, but prevent the 
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passage of large, charged, or potentially dangerous molecules.11,12 This limitation 
creates a challenge for drug treatment of brain tumors, like GBM. Drug delivery to the 
brain is most commonly performed by using either a pharmacological or neurosurgical-
based approach.13 The pharmacological-based approaches use various drug 
conjugations or drug delivery platforms such as self-assembling peptides,14 liposomes,15 
or polymeric drug carriers.15 The pharmacological-based approach uses invasive 
methods that involve intraventricular infusion, intracerebral delivery, and convection-
enhanced diffusion.12 
A common way to improve the delivery of a brain cancer drug is through drug 
lyophilization or conversion of the drug into a lipophilic molecule. Prodrugs for delivery 
across the BBB are formed by linking nonpolar groups to the active molecule,11 allowing 
concealment of the polar groups in the active drug, therefore transforming a water-
soluble drug into a lipid-soluble prodrug.11 The prodrug is then able to cross the BBB and 
is converted to the active drug. Furthermore, if the active drug is polar, exit from the 
brain into the systemic circulation will be hindered.16 Conjugation of drugs, by either 
addition of a nonpolar group or molecular alteration, to form prodrugs are popular due to 
their enhanced BBB permeability.  
1.2.2 Chemotherapeutic Resistance 
Glioblastoma has been found to have either intrinsic or acquired resistance to 
chemotherapy. Acquired drug resistance to chemotherapeutic prodrugs, like 
temozolomide, has been attributed to the (O)6-methylguanine-DNA-methyltransferase 
(MGMT) gene. MGMT is a DNA repair protein that functions by removing alkyl groups 
from the O6 position of guanine, correcting drug-induced DNA damage and preventing 
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apoptosis.6 Therefore, when TMZ and other alkylating agents are used for therapy, they 
encounter resistance due to upregulation of MGMT. Since alkylating agents exert 
therapeutic effects by generating DNA damage, the MGMT status of a patient is strongly 
correlated with chemotherapeutic resistance, and as a result, the efficacy of treatment 
when using alkylating drugs.17 Methylation or lower expression of MGMT has been 
associated with an increase in positive outcomes when treating patients with 
glioblastoma with TMZ.17 
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CHAPTER 2 
RELEASE APPROACHES AND ACTIVATION STRATEGIES FOR PRODRUGS 
2.1 Introduction to Prodrugs 
Prodrugs are used extensively in the delivery of cytotoxic compounds to cancer 
cells. The development of successful therapies for cancer treatment is increasingly 
challenging due to the barriers that diminish drug efficacy. These difficulties potentially 
affect the drug bioavailability, solubility, and distribution. Consequently, further significant 
issues may arise, such as adverse side effects, shorter drug duration, and reduced drug 
stability.18 In order to overcome these barriers, the use of prodrugs has become an 
effective tool in cancer therapies.  
The term prodrug, introduced by Adrien Albert in 1951, refers to a reversible 
molecule with desirable drug properties, which does not possess any pharmacological 
effects until conversion to its active form.19 The aim behind prodrug design is to mask 
undesirable properties of therapeutics, such as poor water solubility or chemical 
instability.20 This mask allows prodrugs to remain in their inactive form until enzymatic or 
chemical transformation initiates release of the active form of the drug.20 The justification 
behind the use of prodrugs is to improve the overall bioavailability, biodistribution, 
metabolism, excretion, and undesirable toxic effects of the parent drug (or adsorption, 
distribution, metabolism, excretion and toxic properties).20 These properties remain 
muted until the prodrug reaches the targeted tumor or intended site of action.  
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Figure 1.1 Schematic representation of the prodrug concept. (A) Carrier-linked prodrug allow improved 
pharmacokinetics of the drug.  The carrier-linked portion of the prodrug indicates the part of the prodrug that is 
pharmacologically inactive. The barrier represents the limitations of the parent drug that prevent optimal 
pharmacokinetic performance. (B) Carrier-linked prodrugs are activated through enzymatic or non-enzymatic 
cleavage of the drug from the carrier (adapted from Rautio et al. 2008).18 
There are two main classes of prodrugs: carrier-linked prodrugs and bioprecursor 
prodrugs. In carrier-linked prodrugs, the drug is linked to a moiety (or temporary carrier) 
through a bioreversible covalent linkage.21  This carrier generally improves the 
(B)
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Barrier	
(A) 
pharmacokinetics of the drug due to its lipophilic nature, allowing it to overcome barriers 
to optimal pharmacokinetic performance (Fig. 1.1A). To release the parent drug or 
activate the prodrug, the carrier can be easily removed in vivo through enzymatic and/or 
non-enzymatic cleavage22 (Fig. 1.1B). Bioprecursor prodrugs result from molecular 
alteration of the active drug itself. This modification allows the prodrug to be converted 
metabolically or chemically to its active compound.  
Prodrugs are commonly activated in two ways: actively, via enzyme hydrolysis, 
or passively, via reduced pH or hypoxia. Our aim is to present an overview of the two 
prodrug activating strategies. Specifically, we will highlight the common approaches to 
converting prodrugs to their active form.  
2.2 Active Targeting: Enzyme responsive therapies 
Anticancer prodrugs can be designed to target certain molecules, such as 
enzymes and antigens, which are commonly overexpressed in tumor cells.23  Enzyme 
Prodrug Therapy (EPT) is widely-used as a method for converting cancer prodrugs into 
active drugs through hydrolysis in the body. The principal technique of EPT is to deliver 
a drug-activating enzyme to cancerous tissues and then systemically dispense the 
prodrug.23 This method allows local activation of the prodrug, which is essential in 
preventing systemic adverse side effects.  
Activation of prodrugs in tumor tissues by enzymes can be achieved in two ways: 
antibody-directed enzyme prodrug therapy (ADEPT), and gene-directed enzyme prodrug 
therapy (GDEPT)23. Here we discuss strategies for active transformation of prodrugs 
using enzymatic therapies in detail as well as their benefits and limitations. 
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2.2.1 Antibody directed enzyme prodrug therapy (ADEPT) 
Antibody directed enzyme prodrug therapy (ADEPT) was first proposed almost 
30 years ago to overcome the restrictions of early antibody directed cancer therapy.24 
ADEPT is a strategy that uses a drug-activated enzyme attached to a tumor-related 
antibody. After the prodrug is systemically administered, the enzyme located on the 
tumor site will convert the prodrug to its active form. This results in localized cytotoxic 
effects to the tumor due to the targeting of the tumor-related antibody.25 Limitations of 
the ADEPT system include immunogenicity of the antibody, inefficient delivery of 
antibody and enzyme to all tumor cells, and difficulty of producing large amounts of 
active drug, resulting in low levels of cytotoxicity.26  
2.2.2 Gene-directed enzyme prodrug therapy (GDEPT) 
Gene-directed enzyme prodrug therapy (GDEPT), also known as viral directed 
enzyme prodrug therapy (VDEPT) or suicide gene therapy, utilizes a viral vector to 
deliver a gene encoding an enzyme that will convert a prodrug into its active, lethal form 
within a tumor.27 Upon production of the desired enzyme, the systemically delivered 
prodrug can then be activated.27 Common viruses used in GDEPT are adeno-associated 
viruses (AAV), retroviruses, herpes simplex virus (HSV), and Epstein-Barr virus (EBV).25 
Enzymes commonly delivered include thymidine kinase,28 cytosine deaminase,29 and 
cytochrome P450.30 Despite the high delivery efficiency, there are several limitations to 
using viral vectors that still remain. There is a slight risk of the virus reverting to its wild-
type form, causing mutations in the genome.31 Also, most retroviral vectors can only 
integrate into dividing cells, which even in high-grade invasive tumors only represents 
approximately 11.2-23.4% of tumor cells.32 This excludes the type of retroviral vector 
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known as lentiviruses, which are able to infect both proliferating and non-proliferating 
cells.33 Despite this, the majority of tumor cells would not be targeted using retroviruses. 
2.3 Common Enzyme/Prodrug Systems 
2.3.1 Carboxypeptidase G2 (CPG2)/Nitrogen mustard 
The enzyme carboxypeptidase G2 (CPG2) is derived from the Pseudomonas 
strain RS-16.34 CPG2 works by cleaving glutamic acid from nitrogen mustard-based 
drugs creating DNA-alkylating agents with the capacity to methylate DNA.34 The 
activated drug then has the ability to cause DNA cross-linking, which leads to 
apoptosis.35 CPG2 also possesses the ability to diffuse through cell membranes without 
the need for gap junctions, demonstrating versatility compared to other enzymes.35 
Using CPG2 in enzyme-prodrug chemotherapy is effective, but this strategy is hindered 
by the enzymes’ off-site targeting of the prodrug.36 Currently, studies are being 
conducted to create an inhibited version of the enzyme that can be regulated through 
proteolysis by a tumor-specific protease,36 allowing an increase in the localization effects 
of the prodrug and a decrease in off-site targeting. A study conducted by Yachnin et al. 
showed that it is possible to generate a protease-regulatory form of CPG2, which will be 
valuable in upcoming enzyme-prodrug therapy.36  
2.3.2 Herpes Simplex Virus-Thymidine Kinase (HSV-TK)/Ganciclovir 
In the Herpes Simplex Virus-Thymidine Kinase (HSV-TK) system, ganciclovir 
(GCV) is phosphorylated by the thymidine kinase enzyme.35 Following phosphorylation, 
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the triphosphate form of GCV is produced.35 This GCV triphosphate form can then cause 
apoptosis in tumor cells by introducing single-stranded breaks into DNA. Unfortunately, 
GCV can only affect dividing cells, and it has limited transportation capacity because gap 
junctions are required for transport.35 There are also risks in using a viral system, such 
as triggering the immune system, mutations, and restricted migration.35 Recently, 
Hashemi et al. demonstrated in a GBM disease model that the HSV-TK system could be 
improved by incorporating olfactory ensheathing cells (OECs).37 These cells are 
removed from human olfactory mucosa and have the ability to migrate toward 
astrocytes.37 The cells then can deliver the HSV-TK gene to tumorigenic astrocytes, 
inducing cell death. Another study conducted by Wu et al. showed that transfer of GCV 
could be increased by improving a study that used an approach combining two GDEPT 
systems.38  Cell were retrovirally transduced with cytosine deaminase-uracil 
phosphoribosyltransferase and HSV-TK.38 The result of the combination was inhibited 
growth and high therapeutic efficacy in lung metastases.31 Other approaches examined 
the use of valacyclovir, the prodrug form of acyclovir, instead of GCV, and higher 
efficacy was observed.27,35  
2.3.3 Cytosine Deaminase (CD)/5-Fluorocytosine 
In the cytosine deaminase (CD) system, 5-fluorocytosine (5-FC), an antifungal 
prodrug, is converted to its active form, 5-fluorouracil (5-FU), by the enzyme CD.25 After 
conversion, active 5-FU is effective in killing tumor cells but causes side effects, such as 
dermatitis, cardiac toxicity, and mucositis.35 Despite this, 5-FU has the ability to travel 
independently of gap junctions by diffusion, unlike HSV-TK. This feature of 5-FU allows 
the prodrug to induce more cell death than most systems. CD/5-FC has been utilized for 
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treating various types of cancer, including colon,39 liver,39 breast,40 glioma,41 and ovarian 
cancer.29,42 To overcome the weaknesses of CD/5-FC, groups have worked to address 
off-targeting, optimizing the prodrug, and optimizing delivery capacity. Takahashi et al. 
demonstrated that CD/5-FC increases cytotoxic effects in glioma cells in response to the 
radiosensitizing effect of 5-FU.43 Another study combined CD/5-FC with a nonlytic 
retroviral replicating vector (TOCA 511), where TOCA 511 acts as a carrier for cytosine 
deaminase (CD). Ostertag et al. proved that TOCA 511 was capable of effectively 
delivering and activating the prodrug, which resulted in tumor shrinkage and growth 
inhibition.44  
2.3.4 Cytochrome P450 (CYP)/Oxazaphosphorines 
One third of all P450 enzymes are involved in activating anticancer prodrugs.30 
P450 enzyme concentrations differ in various areas of the body, so the P450 enzymes 
may be manipulated to target select tissues or areas for drug activation.30 Anticancer 
prodrugs involved with P450 enzymes are oxazaphosphorines, which include 
Cyclophosphamide (CPA) and Ifosfamide (IFA). These alkylating prodrugs are 
substrates that the P450 enzyme metabolizes to yield a 4-hydroxy derivative product, 
the active form of the prodrugs.35 The yielded product forms DNA cross-links that 
ultimately lead to cell death. Similar to 5-FU, the resulting active prodrug from CPA/IFA 
can be transported independently of gap junctions,35 which provides the system with a 
higher level of potency than others. Another advantage of the CYP system is the 
decrease in immunogenicity due to P450 enzymes already existing in the human body.35 
Lack of specificity is a major weakness of the system because P450 liver enzymes 
metabolize prodrugs, generating active metabolites throughout the entire body instead of 
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in one specific location. This causes serious side effects, including neurotoxicity, 
cardiotoxicity, and nephrotoxicity.35 However, a few approaches have been used to 
reduce systemic toxicity. In one approach, encapsulated cells overexpressing the CYP 
enzyme were implanted around malignant mammary tumors, and the patients were 
given CPA following implantation. The results showed no adverse systemic side 
effects.45 Despite these promising results, there are still fears about using the CYP 
system due to the systemic activation of CYP450 in humans.  
2.3.5 Summary 
There has been significant progress in the development of enzyme/prodrug 
systems. Developing safe vectors and enzymes to achieve local drug delivery and 
prevent off-target effects remains the focus of current research. Efforts are being made 
to move away from traditional prodrug activation methods due to their instability and 
other drawbacks mentioned previously. For example, Du et al. has developed metal-
contained enzyme mimics (MEMs) for prodrug activation. These MEMs can copy the 
functions of natural enzymes and be used for prodrug activation.46 Overcoming these 
issues may increase the possibility of eradicating incurable and hard to treat cancers.  
2.4 Passive Targeting: Environment Responsive Therapies 
Unlike active targeting, which utilizes enzymes or antigens, passive targeting 
exploits the pathophysiological abnormalities that result from malignant tissue.47 These 
abnormalities include the hypoxic environment of tumor tissue and the difference in 
intracellular pH. These changes can be manipulated beneficially by designing prodrugs 
that will selectively activate in these tumor environments. Here we discuss common pH-
responsive linkages and hypoxia-activated prodrugs (HAPs). 
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2.4.1 pH Responsive 
The intracellular pH within solid tumors is maintained near a pH range of 5.7-7.6 
due to the buildup of acid metabolites resulting from an imbalance of metabolic rates, 
glucose consumption rates, and proton transport.48 Therapeutic strategies have been 
designed to exploit tumor pH by using prodrugs which activate at low pH. pH-responsive 
prodrugs can be attained through drug conjugation to cleavable acid-linkages. Common 
pH-responsive linkages include acetals, anhydrides, and hydrazones.49 These linkages 
are bonded to the drug, rendering it inactive or in prodrug form, until the chemical bonds 
are cleaved at a low pH to allow drug hydrolysis.50 Hydrazone linkages have 
demonstrated fast hydrolytic cleavage at a low pH compared to a neutral physiological 
pH.50 Alendronate-monoethyl adipate-hydrazone (ALN-MA-hyd) has been used as a 
linker for doxorubicin (DOX) to deliver the chemotherapeutic to bone tumor tissue.51 The 
conjugate released DOX at a pH of 5, and also proved to be relatively stable at 
physiological pH.52 In another study, a hydrazone bond was used to conjugate DOX to a 
di-block copolymer composed of poly(L-lactic acid) (PLLA) and methoxy-poly(ethylene
glycol) (mPEG).51 The study showed that in an acidic environment of pH 3 or 5, most of 
the DOX was cleaved from the hydrazone linkage, allowing for DOX to hydrolyze and 
mediate cell death. At a pH of 7, the amount of DOX released was less than 10%, which 
confirmed that the encapsulated DOX remained stable at neutral pH.51 The DOX-
conjugated polymer allowed for increased drug uptake in lymphoblast cells at a low pH 
and slower release of DOX at a physiological pH.51 
2.4.2 Hypoxia Responsive 
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The environment within most tumors contains areas of hypoxia due to poor blood 
supply, or a state of low oxygen, which is known to promote tumor resistance to 
chemotherapy and radiotherapy.53 Oxygen is a radiosensitizer, a molecule that facilitates 
oxidation of free radicals in DNA during tissue irradiation.54 Thus, hypoxic tumor cells are 
resistant to radiotherapy. The hypoxic tumor cells are also resistant to most 
chemotherapies, due to the tumor cells being quiescent and chemotherapeutic drugs 
only targeting proliferating cells.53 Chemotherapy and radiotherapy resistance is also 
often due to the development of an aggressive phenotype that promotes resistance to 
apoptosis, inhibition of DNA repair, increased angiogenesis, metastasis, and an 
abundance of other effects.53 Thus, the therapeutic strategy of hypoxia-activated 
prodrugs (HAPs) was developed to target hypoxic tumors.  
PR104 is a nitroaromatic compound, a water-soluble phosphate ester, which 
upon activation, quickly hydrolyzes in a hypoxic environment into an alcohol, PR104A.55 
PR104A is then metabolized by oxidoreductases in the body, which results in DNA 
cross-linking or cell death.53,55 Studies have shown that PR104 could be used to 
eradicate acute myeloid leukemia and acute lymphoblastic leukemia.55 Patients with 
these diseases are known to exhibit high levels of hypoxia at their tumor sites.55 In a 
phase I/II study, PR104 was given to patients with refractory or relapsed acute myeloid 
leukemia or acute lymphoblastic leukemia. The patients were administered an 
intravenous infusion of PR104 every 14-28 days for up to 3 cycles. Overall, the study 
demonstrated PR104 effectiveness, but due to the toxicity of PR104, it is unlikely to be 
successful long-term.55 
TH-302 is a hypoxia-activated prodrug of bromo-isophosphoramide. Reduction of 
the nitrogen group on TH-302 causes the prodrug to release a DNA-crosslinking 
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alkylating agent in hypoxic regions.53 Studies have shown that TH-302 can be utilized for 
a broad range of applications, but is most commonly used to treat myeloma. In one 
study, TH-302 was used to target hypoxic bone marrow niches in leukemia and the 
results showed that leukemia cells were reduced when treated with TH-302.56 The study 
also showed that using TH-302 followed by chemotherapy increased survival in mice.56 
Despite in vivo success, phase III clinical trials did not show effective results.56 This was 
due to side effects, such as myelosuppression. TH-302 is selective by only affecting 
hypoxic areas and shows potential for targeted therapy in cancer treatment.  
2.4.3 Conclusion 
One of the key advantages of pH-responsive prodrugs is that they are able to 
exploit tumor tissue pH for activation. These pH-responsive prodrugs allow efficient 
delivery at the tumor site and minimization of harmful off-target side effects. Despite this, 
pH-responsive delivery systems have not performed well in clinical studies for cancer 
therapy. This is due to ineffective translation of the in vitro properties to in vivo studies.57 
Hypoxia-activated prodrugs are useful for targeting hypoxic tumors. These 
tumors are known for being difficult to treat, and this particular strategy offers an 
advantage for treating aggressively resistant tumor types. However, the therapeutic 
benefit of hypoxia-activated prodrugs is currently limited. The toxicity associated with the 
use of the hypoxia-activated prodrugs, along with the lack of prodrug optimization, 
reduces the clinical potential of this strategy.  
2.5 Conclusion/Final Remarks 
Bioengineering strategies have been explored to improve the release or 
activation of prodrugs through active or passive activation methods. Active targeting 
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methods that involve enzyme/prodrug systems are effective but include many unsafe 
delivery vectors and enzymes. Passive targeting methods, which rely on environment 
activation, allow for more efficient, local delivery, and in turn a reduction of harmful side 
effects. Despite this, passive targeting systems still lack effective translation to in vivo 
studies. The future of prodrug therapy for both targeting methods begins with the 
development of safer delivery systems, along with prodrug optimization for effective 
translation to clinical trials.  
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CHAPTER 3 
RESEARCH AIMS 
3.1 Objectives 
Gliomas represent approximately 80% of all malignant brain tumors, and 
glioblastoma multiforme (GBM) accounts for nearly half of all gliomas.1 GBM is the most 
common and aggressive primary brain tumor. Despite aggressive treatment including 
tumor resection followed by radiation and chemotherapy, the median survival rate for 
GBM is 15 months.2 Therefore, new therapeutic strategies are needed to improve the 
survival rate of those affected by GBM.  
The objective of this research is to target GBM by developing a local anticancer 
drug delivery system using peptides, that will self-assemble in water to form a hydrogel. 
Chemotherapy with the DNA alkylating agent, Temozolomide (TMZ), is used as a first-
line treatment for GBM. Studies have shown that full conversion of TMZ to its active form 
occurs at a more basic pH (pH>7.5).5 Furthermore, after TMZ is converted to its active 
form, it is unable to cross the blood brain barrier, thereby limiting availability in the brain 
and lowering the effectiveness of TMZ. Therefore, my central hypothesis and the overall 
goal of this research is to develop an innovative local delivery strategy using hydrophilic 
and alternating hydrophobic and acidic amino acids to form a hydrogel that will 
encapsulate TMZ and convert the drug to its active form.  
By pursuing the following aims, I will gather the data essential to develop a 
delivery system that will improve the efficacy of TMZ and extend the survival rate for 
patients with GBM. The study aims are listed and discussed below. 
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Aim 1: Determine whether the peptide compositions/designs will allow for loading 
of the anticancer prodrug. To accomplish this aim, we will design, synthesize, and test 
the ability of three different peptides to load TMZ. These peptides will differ in number of 
hydrophobic and hydrophilic sites. Based on this and the hydrophobic nature of TMZ, we 
hypothesize that the peptides will be able to load TMZ. We also believe that increasing 
the number of hydrophobic amino acids will allow for loading of more TMZ.  
Aim 2: Characterize the structural properties of peptide hydrogels. We will 
determine the sizing, zeta potential, formation of secondary structures, and release 
profile of each peptide hydrogel. We hypothesize that the release of drug from each 
peptide will be associated with the ratio of hydrophobic to hydrophilic amino acids. We 
also hypothesize that sizing of each peptide hydrogel will be relatively similar, there will 
be formation of secondary structures, and the zeta potential will correlate with the 
amount of charged amino acids of each peptide.  
Aim 3: Assess drug release from the loaded peptide hydrogels. To accomplish this 
aim, we will load a dye into the hydrogels and measure the change in fluorescence over 
time. We hypothesize that dye release will be slower in the peptide hydrogel that 
consists of more hydrophobic amino acids, and faster in the peptide hydrogels with less 
hydrophobic residues.  
Aim 4: Determine the cell viability of human glioblastoma cells treated with the 
TMZ-loaded peptide hydrogel compared to TMZ delivered alone. Each peptide-
hydrogel loaded with TMZ will be delivered onto LN-18 cells and assessed for an 
increase in cytotoxicity. We hypothesize that increased conversion of TMZ into its active 
form will be based on the number of basic amino acids in each peptide.  
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3.2 Approach 
Aim 1: 
We will first evaluate whether TMZ is more active/cytotoxic when dissolved in a 
basic pH environment and delivered onto human glioblastoma (LN-18 and T98G) cells. 
This will be performed to determine whether our peptide designs will potentially be 
effective in conversion of TMZ into its active form.   
Aim 2: 
Once the appropriate peptide compositions have been chosen, the peptide 
hydrogels will be characterized using circular dichroism (CD) for secondary structure 
analysis, zeta potential for structure stability, and dynamic light scattering to measure 
particle size. After the assessment of TMZ in a basic environment, and characterization 
of the peptide hydrogels, the amount of TMZ loaded will be assessed. TMZ will be 
loaded into the peptide hydrogels at 3 peptide concentrations (0.05, 0.1, and 0.5 mg/mL) 
and a TMZ concentration of 200 µM. The amount of loaded TMZ will be determined by 
high-performance liquid chromatography (HPLC). 
Aim 3:  
Based on the TMZ loading results, the peptide concentration that exhibited the 
maximum amount of loading will be selected for the release and cytotoxicity study. To 
study release, phenol red will be loaded into each peptide hydrogel. The peptide 
hydrogels will then be incubated at 37°C. The absorbance of phenol red will be taken at 
several time points to determine the amount released over time.   
Aim 4: 
Lastly, the cytotoxicity of the TMZ-loaded peptide hydrogels in human 
glioblastoma (LN-18) cells will be evaluated by MTT assay. 
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CHAPTER 4 
IMPLANTABLE SELF-ASSEMBLING PEPTIDE-HYDROGEL DRUG DELIVERY 
SYSTEM FOR TREATING GLIOBLASTOMA MULTIFORME 
Temozolomide (TMZ) has been used for anticancer treatment since its approval 
in 1999.6 TMZ is a slightly hydrophobic prodrug, that is able to exert its anticancer 
effects by methylation of purine bases of DNA, including O6-guanine, N7-guanine, and 
N3-adenine, initiating base pair mismatches.7,58 TMZ is delivered orally and known to 
remain stable in its native form in the acidic environment of the stomach. The drug is 
absorbed in the bloodstream and begins to convert into its active form, known as 5-(3-
methyltriazel-1-yl)-imidazo-4-carboxamide (MTIC), at a neutral or physiological pH.5 
However, studies have shown that full conversion of TMZ into its active form occurs at a 
more basic pH (>7.4),5 suggesting that the therapeutic effect of TMZ is limited. Further, 
TMZ is the standard-of-care chemotherapy drug for treating patients with glioblastoma, 
but the median survival rate remains low at 14.6 months with aggressive treatment.6 
Development of carriers tailored to the mechanism activating TMZ have not been 
previously explored but may enhance the effectiveness of the drug. 
Peptides that are able to self-assemble into different nanostructures are very 
attractive for biomedical applications such as drug delivery. These self-assembling 
peptides are advantageous due to their biocompatibility and high loading capacity for 
hydrophilic and hydrophobic drugs.59 These peptides are able to self-assemble due to 
hydrogen bonding, hydrophobic interactions, and electrostatic interactions that combine 
and form stable nanostructures.60 Among these self-assembling peptides is a class of 
peptides that are able to self-assemble into hydrogels when introduced to water. This is 
due to the alternating hydrophilic and hydrophobic nature of the amino acids.61 Recently, 
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self-assembling peptides have been utilized as local delivery systems for protein drugs 
and hydrophobic anticancer drugs or agents.61 To facilitate the delivery of TMZ, and 
potentially other hydrophobic prodrugs, we developed a novel peptide hydrogel delivery 
system.  
The peptides were designed and consisted of basic and alternating hydrophobic 
and acidic amino acids. We demonstrated that at various concentrations, the peptide 
hydrogels are able to efficiently load TMZ, and the release profiles can be adjusted 
based on peptide composition. In vitro experiments confirmed that TMZ dissolved at a 
higher pH resulted in significantly increased cytotoxicity in LN-18 and T98G human 
glioblastoma cells. Studies also showed that TMZ-loaded peptide hydrogels exhibited 
greater anticancer activity in LN-18 cells compared to delivery of TMZ alone.  
4.1 MATERIALS AND METHODS 
4.1.1 Materials 
Peptides AE12K4 (AEAEAEAEAEAEKKKK-), AE8K8 (AEAEAEAEKKKKKKKK), 
and AE4K12 (AEAEKKKKKKKKKKKK) were synthesized and purified (purity >95%) by 
GenScript USA Inc (Piscataway, NJ). The N and C terminals of the peptides were 
protected by acetyl and amino groups, respectively. TMZ (³98% pure), Phenol Red, and 
Thiazolyl Blue Tetrazolium Bromide (TBTB) were purchased from Sigma-Aldrich (St. 
Louis, MO). The LN-18 and T98G human glioblastoma cell lines were obtained from 
ATCC (Manassas, VA). The LIVE/DEAD Viability/Cytotoxicity Kit as well as cell culture 
reagents, including fetal bovine serum (FBS), penicillin-streptomycin, and trypsin were 
acquired from ThermoFisher Scientific (Waltham, MA). Cell culture medium DMEM, 
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EMEM, and Methanol (³99% pure) were obtained from VWR (Radnor, PA). pH buffers 
were obtained from ThermoFisher Scientific.  
4.1.2 Cell Culture 
The human glioblastoma cell line LN-18 was cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) with 10% fetal bovine serum (FBS), and 1% antibiotic (100iU/mL 
penicillin/100ug/mL streptomycin). The human glioblastoma cell line T98G was cultured 
in Eagle’s Minimum Essential Medium (EMEM) with 10% fetal bovine serum (FBS), and 
1% antibiotic (100IU/mL penicillin and 100ug/mL streptomycin). Both cell lines were 
grown in an incubator at 37°C with 5% CO2. 
4.1.3 Cytotoxicity of TMZ at various pH 
To determine whether the anticancer activity of TMZ is pH dependent, 
cytotoxicity of TMZ on glioblastoma cells was examined in various pH environments. LN-
18 or T98G cells were plated at 1X105 or 0.9X105 cells per well in 24-well plates and 
allowed to attach overnight. TMZ was dissolved in water at a pH of 2.5, 7.5, and 12. TMZ 
from each pH environment was added to LN-18 and T98G cells for a final concentration 
of 200 µM and allowed to incubate in media containing 10% FBS. After 24 hours, cells 
were washed three times with media to remove TMZ and incubated for an additional 48 
hours. Cytotoxicity of TMZ was determined by MTT assay after a total of 72 hours. For 
the MTT assay, Thiazolyl Blue Tetrazolium Bromide (TBTB) was dissolved in PBS at 2 
mg/mL and added to media on cells for a final concentration of 1 mg/ml. After a 4-hour 
incubation at 37°C, the media containing TBTB was aspirated from the wells, and 500 
µL of DMSO was added to each well to dissolve the formazan crystals. A Biotek Synergy 
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plate reader (Winooski, VT) was used to measure absorbance at 540 nm. Cell viability 
was normalized to untreated cells and determined by using the following equation:  
Cell viability (%) = (Absorbance540(sample)/Absorbance540(control)) x 100%. 
4.1.4 Preparation of TMZ-loaded Peptide Hydrogels 
To prepare the peptide hydrogels, AE12K4, AE8K8, and AE4K12 peptides were 
dissolved in a solution of 90% ethanol and 10% Milli-Q water at concentrations of 0.05 
mg/mL, 0.1 mg/mL, and 0.5 mg/mL. TMZ was dissolved in Milli-Q water and combined 
with each peptide solution for a final TMZ concentration of 200 µM. The final solution 
was dehydrated to form a transparent drug-loaded film. The film was washed 3 times 
with Milli-Q water to remove any unloaded or residual TMZ. Milli-Q water was then 
added to rehydrate the film and allowed to shake for 2 hours. The amount of TMZ loaded 
was determined by high-performance liquid chromatography (HPLC).  
4.1.5 Characterization of Peptide Hydrogels 
Zeta Potential and Dynamic Light Scattering 
To determine the surface charge (zeta potential) and particle size of the peptide 
hydrogel assemblies, laser doppler velocimetry combined with phase analysis light 
scattering (M3-PALS) and dynamic light scattering, respectively, was conducted on the 
peptide hydrogels prepared at a concentration of 0.05 mg/mL using a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK). The temperature of the Zetasizer was maintained at 
25°C. The intensity of scattered light due to the complexes was collected at an angle of 
173°, a refractive index of 1.6, and an absorbance value of 3.27. Three measurements 
were tested to generate an intensity-based size distribution plot.  
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CD Measurement 
The peptide hydrogels were prepared at a concentration of 0.05 mg/mL and a 
CD spectrum between 190 nm and 300 nm was recorded on a Jasco J-810 CD 
Spectropolarimeter (Jasco, Inc., Easton, MD) at 20°C. All spectra were corrected by 
subtracting the baseline and the data was expressed as the mean residue of ellipticity, 
which was given in units of degrees per cm2/dmol. Predicted percentages of 𝛼-helices 
and β-sheets were determined using CAPITO,61 a web server-based analysis and 
plotting tool for CD data. 
4.1.6 Determination of TMZ Loading in Peptide Hydrogels 
The amount of TMZ loaded into each rehydrated peptide hydrogel was 
determined using an HPLC system consisting of a Waters Model 2707 Autosampler 
connected to a 1515 Isocratic HPLC Pump (Waters, Inc., Milford, MA). Samples were 
injected onto the reverse phase Zorbax Rx-C18 column (4.6 x 250 mm, 5 µm). The 
absorbance detector was set at 316 nm. The mobile phase consisted of 0.1% aqueous 
acetic acid in Milli-Q water and methanol (90:10, v/v) and was delivered at 1.0 mL/min. 
The amount of drug loading was determined by comparison to the given temozolomide 
concentration (0.03 mg/mL).  
4.1.7 Release of TMZ from Peptide Hydrogels in vitro 
0.05 mg/mL of AE8K8 and AE4K12 peptide hydrogels, and 0.5 mg/mL of 
AE12K4 peptide hydrogel was prepared as previously described in section 4.1.4. Instead 
of TMZ, phenol red was loaded into the peptide hydrogels at a final concentration of 200 
µM. To study release kinetics, the phenol red-loaded peptide hydrogels were placed into 
a 96-well plate and incubated at 37°C. The absorbance of the phenol red was measured 
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using a Biotek Synergy plate reader at 443 nm. The absorbance of each sample was 
measured at 0, 1, 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours. The amount of phenol red 
released from the peptide hydrogel was calculated by comparison to the absorbance 
value taken at the initial time point. The percentage of phenol remaining was determined 
by using the equation below:  
Amount Remaining (%) = (Absorbance443(Time X)/Absorbance443(Time 0)) x 100%. 
4.1.8 Cytotoxicity of TMZ-Loaded Peptide Hydrogels 
To analyze the anticancer activity of the TMZ-loaded peptide hydrogels, a 
cytotoxicity study was performed. LN-18 (1X105) cells were cultured in 24-well plates 
and allowed to attach overnight. AE12K4, AE8K8, and AE4K12 peptide hydrogels were 
formed at the concentration that exhibited the highest TMZ loading for each peptide. The 
TMZ-loaded peptide hydrogels were incubated with LN-18 cells at 200 µM for 72 hours 
in media containing 10% FBS. Cells were treated with TMZ alone, unloaded peptide 
hydrogel, or left untreated as controls. Cytotoxicity of TMZ was determined by MTT 
assay after the 72-hour incubation period and cell viability was calculated as previously 
described in section 4.1.3. 
4.1.9 Statistical Analysis 
Quantitative data were presented as mean ± SEM or standard deviation of three 
independent experiments. Statistical analysis was performed using either Student’s t-test 
or one-way ANOVA, where *P<0.05, **P<0.01. ***P<0.001, ****P<0.0001. A value of 
P<0.05 was considered statistically significant.  
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4.2 RESULTS 
4.2.1 Peptide design and structure of peptide hydrogels 
Three different compositions of self-assembling peptides were designed, each 16 
amino acids in length, consisting of Alanine (A) as the hydrophobic domain, Glutamic 
acid (E) as the hydrophilic/acidic domain, and Lysine (K) as the hydrophilic/basic domain 
(Fig. 4.1). The peptides were synthesized and designed with alternating hydrophobic 
and hydrophilic amino acids to promote self-assembly into a hydrogel when water is 
introduced. The rationale for this design is that TMZ will load into the hydrophobic core 
and maintain stability due to the acidic amino acid residues (Fig. 4.2). As the hydrogel 
degrades, the basic amino acids will convert TMZ into its active form.  
Figure 4.1. Peptide design and structure of peptide. AE12K4 (A), AE8K8 (B), and AE4K12 (C) peptides 
were designed using peptide sequences consisting of alanine, glutamic acid, and lysine.  
(A) 
(B) 
(C)
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 4.2.2 Cytotoxicity of TMZ versus pH 
TMZ begins to convert to its active form, MTIC, at neutral pH; however, previous 
studies have demonstrated that TMZ only fully converts to MTIC at a more basic pH 
(>7.5).5 Though this has been shown, the effectiveness of TMZ when dissolved in 
different pH environments has not been previously reported in the literature. Therefore, 
to determine whether the anticancer activity of TMZ is pH dependent, a cytotoxicity study 
was performed on human glioblastoma cells with TMZ dissolved in basic, neutral, and 
acidic pH environments. The results showed that TMZ exhibited slight anticancer activity 
at a pH of 2.5, but as the pH was increased, the anticancer activity of TMZ was 
significantly enhanced in both LN-18 (Fig. 4.3A) and T98G (Fig. 4.3B) human 
glioblastoma cell lines. Viability of cells treated with neutral TMZ was 56% and 83% in 
LN-18 and T98G cells, respectively.  Viability decreased by at least 25% when cells 
were treated with basic TMZ compared to neutral TMZ, with viabilities of 30% and 58% 
in LN-18 and T98G cells, respectively.  These results demonstrate that the effectiveness 
of TMZ is pH dependent and TMZ has the largest anticancer activity when dissolved in a 
basic pH environment. These results validate the potential utility of basic pH amino acids 
Figure 4.2.  Schematic of TMZ loading into peptide hydrogel. Alternating hydrophobic and hydrophilic 
amino acids were used to promote self-assembly of a hydrogel. TMZ will load into the hydrophobic portion 
and maintain stability due to the acidic amino acid residues. As the hydrogel degrades, the basic amino acids 
will convert TMZ into its active form.  
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residues in the design of the peptide hydrogels to increase the anticancer activity of 
TMZ. 
4.2.3 Characterization of Peptide Hydrogels 
Figure 4.3. pH-dependent cytotoxicity of TMZ in LN-18 and T98G cells. Cell viability of (A) LN-18 and 
(B) T98G human glioblastoma cells 72 hours after treatment with TMZ dissolved in water at a pH of 2.5,
7.5, and 12. Data are mean ± SEM of three independent experiments performed in triplicate, where
**P<0.01 and ***P<0.001 compared to untreated cells (control) which were considered 100% viable.
(A) 
(B) 
***	
****	
***	
**	
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After formulating AE4K12, AE8K8, and AE12K4 peptide hydrogels, we 
characterized the particle size, zeta potential, and secondary structures of each peptide 
hydrogel. Circular dichroism (CD) spectroscopy was used to measure the secondary 
structure of each peptide design. The AE12K4 peptide hydrogel displayed a typical 𝛼-
helical spectra with negative peaks at 208 nm and 222 nm (Fig. 4.4A). The AE8K8 
peptide hydrogel exhibited a β-sheet peak at 215 nm as well as an	𝛼-helix peak at 208 
nm (Fig. 4.4B). CD analysis of AE4K12 peptide hydrogels revealed a standard β-sheet 
structure with a negative peak at 215 nm (Fig 4.4C).  
Figure 4.4. Circular Dichroism (CD) analysis of the secondary structure of peptide hydrogels. CD 
examination of the secondary structure of (A) AE12K4, (B) AE8K8  and (C) AE4K12 peptide hydrogels. (D) 
Predicted proportions of secondary structures based on wavelength and mean residue ellipticity values taken 
from CD results.  
A) B) 
C)
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The particle size and zeta potential of each peptide design was tested by DLS 
and M3-PALS, respectively, at a concentration of 0.05 mg/mL. The mean particle sizes 
determined using the Zetasizer ZS were 189.4 nm, 186.3 nm, and 248.3 nm for AE12K4, 
AE8K8, and AE4K12 unloaded peptide hydrogels, respectively (Fig. 4.5A-C). The zeta 
potential, an indicator of surface charge and stability, increased with the increasing 
addition of lysine residues due to the positive charge of the lysine amino acid. The mean 
zeta potentials were -10.6mV, -4.54mV, and 9.56mV for AE12K4, AE8K8, and AE4K12 
peptide hydrogels, respectively (Fig. 4.5D).  
Figure 4.5. Size and zeta potential of peptide hydrogels. Particle size distribution of (A) AE12K4, (B) AE8K8, 
and (C) AE4K12 unloaded peptides hydrogels and (D) zeta potential were characterized using dynamic light 
scattering. Data in table (D) are reported as mean ± standard deviation of peptide hydrogels analyzed in 
triplicate. 
(A) 
(B) 
(C) 
(D)
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4.2.4 TMZ is efficiently loaded into peptide hydrogels 
To assess whether TMZ could be loaded into AE4K12, AE8K8, and AE12K4 
peptide hydrogels, we determined the amount of TMZ in drug-loaded peptide hydrogels 
using HPLC. Drug loading ability of each peptide hydrogel composition was examined at 
multiple concentrations, including 0.05, 0.1, and 0.5 mg/mL. TMZ was dissolved and 
loaded into each formulation at a final concentration of 200 µM. The drug loading 
efficiency was calculated for each peptide hydrogel. The maximum drug loading 
efficiency for each peptide hydrogel was at least 85%, shown in figure 4.6. Based on 
these findings, we selected the peptide concentration with the highest TMZ loading for 
each peptide composition for further experimentation.  
Figure 4.6. TMZ drug loading efficiency in peptide hydrogels. The amount of TMZ loaded for each peptide 
hydrogel composition was determined at peptide concentrations of 0.05, 0.1, and 0.5 mg/mL 
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4.2.5 Release Profiles of TMZ-Loaded Peptide Hydrogels 
To examine the effect that peptide composition has on drug release, phenol red, 
a pH indicator and dye, was loaded into each peptide hydrogel. The color change or 
absorbance of phenol red from each peptide hydrogel was determined over time. The 
results in figure 8A showed the AE12K4 peptide exhibited the slowest release, the 
AE8K8 released faster, and the peptide with the fastest release was the AE4K12 
peptide. Phenol red exhibits a color change from yellow to red as pH increases. To 
confirm the change in pH and rate of degradation, images of each peptide hydrogel 
containing phenol red were taken (Fig 4.7B). The well containing the AE4K12 peptide 
hydrogel shows a faster color change or release of the phenol red dye. The AE12K4 and 
AE8K8 peptide hydrogels start to exhibit a noticeable color change at day 3. This color 
change confirms the phenol red absorbance measured over time represented in Figure 
4.7A.  
33	
Figure 4.7. Release of phenol red from peptide hydrogels. (A) Graph showing absorbance of phenol red as 
a function of time. (B) Images taken during experiment, with the color intensity increasing as a result of phenol 
red pH change.  
4.2.6 Effect of TMZ-Loaded Peptide Hydrogels on Glioblastoma Cells in vitro 
To evaluate the therapeutic potential of TMZ-loaded peptide hydrogels, 
cytotoxicity of the drug-loaded hydrogels was determined using LN-18 cells at each 
peptide composition. Cells were treated with TMZ alone, unloaded peptide hydrogel, or 
TMZ-loaded peptide hydrogels at a TMZ concentration of 200 µM. The amount of TMZ 
alone delivered onto cells was based on the highest amount of TMZ loaded into each 
peptide (Fig 4.8). The percent viability of the LN-18 cells treated with TMZ alone was 
(A) 
(B)
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69% at the TMZ concentration of 200 µM. The percent viabilities of the LN-18 cells 
treated with the peptide hydrogels were 72%, 54%, and 44% for AE12K4, AE8K8, and 
AE4K12, respectively. These results were compared to the cytotoxicity of TMZ delivered 
alone. The cytotoxicity of TMZ delivered by the AE8K8 and AE4K12 peptide hydrogels 
were found to be statistically significant compared to delivery of TMZ alone. Overall, 
these results demonstrate that each peptide design has either similar efficacy or is more 
effective in delivering TMZ into glioblastoma cells than TMZ alone.   
Figure 4.8. Peptide hydrogels enhance the anticancer effect of TMZ in vitro. Quantitative analysis of LN-18 cell 
viability via MTT assay following 72-hour incubation with TMZ loaded into AE12K4 peptide, AE8K8 peptide, 
and AE4K12.  Data are mean ± SEM of three independent experiments performed in triplicate, where **P<0.01 
compared to TMZ treated cells.  
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CHAPTER 5 
DISCUSSION 
In this study, we developed a delivery strategy for TMZ that uses amino acids to 
form a hydrogel that encapsulates the prodrug and converts it into its active form. We 
demonstrated the efficacy of the delivery system, confirming the potential of the TMZ-
loaded peptide hydrogel as a new treatment strategy for glioblastoma, which increases 
TMZ anticancer activity and may ultimately result in improved therapeutic efficacy. 
Furthermore, the peptide hydrogel may allow for delivery of smaller dosages of TMZ, 
which could decrease the toxic side effects of the drug.  
Our results demonstrate the pH-dependent efficacy of TMZ in human 
glioblastoma cells. This is particularly significant because though the pH driven 
activation of TMZ has been shown,5 to our knowledge, the pH-dependent efficacy of the 
drug on cancer cells has not been previously reported. Our results confirm that the 
anticancer activity of TMZ is significantly greater when the drug is dissolved at basic pH 
compared to neutral or acidic pH. This result aligns with studies demonstrating that TMZ 
is only partially activated at neutral pH and has implications on the current clinical 
strategy for delivery of TMZ.5 Oral delivery of TMZ relies on the conversion of the drug to 
its active form at physiological pH once it reaches the bloodstream.62 The low 
therapeutic efficacy of TMZ seen clinically in glioblastoma patients7 may in part be due to 
the incomplete conversion of TMZ at physiological pH, resulting in limited anticancer 
activity, as we have demonstrated in vitro.  This experiment validated the potential of our 
peptide hydrogel design including acidic and basic amino acids to improve the efficacy of 
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TMZ.  Acidic amino acids are included in the interior to provide stability since TMZ is 
stable as a prodrug at acidic pH,62 which we also confirmed in vitro; TMZ dissolved in an 
acidic environment was only slightly cytotoxic to glioblastoma cells. Basic amino acids 
are included on one end of the peptide to mediate the conversion of TMZ to its active 
form upon release from the hydrogel. 
After the peptides were designed and synthesized, we conducted 
characterization studies to evaluate the size, stability, and secondary structures of each 
peptide hydrogel. The diameter of all the peptide hydrogels ranged from 150-300 nm. 
Nanoparticles are ideal for systemic delivery of cancer therapeutics due to their small 
size;63 therefore, the TMZ-loaded peptide hydrogels may have the potential for 
intravenous delivery. The stability and potential cytotoxicity can be verified by the zeta 
potential measurements. Values between +30mV to -30mV are considered to be less 
stable and are more likely to coagulate or gel. The zeta potential of the peptide designs 
ranged from -10mV to +10mV, indicating more slightly charged or neutral hydrogels. 
Circular dichroism (CD) spectroscopy was used to understand the secondary structures 
of the peptides. The AE4K12 peptide hydrogel displayed a typical β -sheet structure with 
a negative peak at 215 nm. The AE8K8 peptide hydrogel displayed a β-sheet peak at 
215 nm, but also an α-helix peak at 208 nm. AE12K4 peptide hydrogels displayed a 
typical 𝛼-helical structure with a negative peak at 208 nm and 222 nm. The formation of 𝛼-helices and/or random coils are due to the number of repeated patterns of 
hydrophobic and charged amino acid residues. The presence of lysine amino acids can 
explain the formation of more β-sheet structures, which is most likely due to better 
crosslinking of the peptide. We found it difficult to achieve a high count number when 
using the zeta sizer. This could be due to the low peptide concentration chosen or the 
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peptide index of refraction being too similar to water. Further studies using scanning 
electron microscopy (SEM) need to be conducted to further confirm the sizing of each 
peptide hydrogel.   
Following characterization, we demonstrated that the peptide hydrogels 
efficiently loaded TMZ, with an average loading efficiency of at least 85%. The AE12K4 
peptide hydrogel was found to load the greatest amount of TMZ and also exhibited an 
increase in loading capacity with increasing peptide concentration. The AE8K8 and 
AE4K12 peptide hydrogels required higher peptide concentrations than the 
concentrations tested to increase loading, likely due to smaller hydrophobic regions 
compared to the AE12K4 peptide. These results demonstrate that hydrophobic drug 
loading capacity increases with increasing number of alanine amino acids. Future work 
should include optimizing TMZ loading into each peptide hydrogel, as well as attempting 
to load other alkylating prodrugs to demonstrate the versatility of the delivery system. 
The release profiles of each peptide hydrogel loaded with phenol red dye was 
then examined. We found that the AE12K4 peptide had the slowest rate of pH change 
over time, and the release rate did in fact increase with the reduction of alanine amino 
acids. We hypothesized that including alanine residues in the peptide design would allow 
for an increase in release rate, due to the hydrophobic nature of alanine. Our results 
demonstrate the tunability of the peptide hydrogels, or the ability to adjust the rate of 
drug release from the delivery vehicle.  
To determine the efficacy of TMZ-loaded peptide hydrogels, cytotoxicity studies 
were performed using LN-18 human glioblastoma cells. We found TMZ-loaded AE12K4 
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peptide hydrogels exhibited anticancer activity similar to delivering TMZ alone. The TMZ-
loaded AE8K8 and AE4K12 peptide hydrogels increased cytotoxicity in LN-18 cells by 
approximately 15% and 25% respectively, compared to TMZ alone. We hypothesized 
that including lysine resides in the peptide design would enable conversion of TMZ into 
its active form. Our results demonstrate that the efficacy of TMZ increases with the 
number of basic amino acid residues included in the peptide design. Efficacy could also 
be affected by slower release of TMZ from AE12K4 and AE8K8 peptide hydrogels 
caused by the additional alanine amino acids. Future studies will include the T98G 
human glioblastoma cell line to evaluate the effectiveness of the TMZ-loaded peptide 
hydrogel on a more resistant cell line. A TUNEL assay that quantifies the apoptotic 
activity of cells, may also be attempted for future studies. Due to the mechanism in 
which TMZ causes cell death, the TUNEL assay may be a more suitable method in 
confirming the efficacy of the delivery system. 
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CHAPTER 6 
CONCLUSION 
In conclusion, our in vitro results confirmed that TMZ is more effective in a basic 
pH environment, likely due to increased conversion of the drug to its active form, 
validating the design of our peptide hydrogels. We demonstrated that AE12K4, AE8K8, 
and AE4K12 peptide hydrogels efficiently load TMZ and their release profiles can be 
adjusted based on peptide composition or the hydrophobic to hydrophilic amino acid 
ratio. Further, the AE8K8 and AE4K12 TMZ-loaded peptide hydrogels increased 
anticancer activity in human glioblastoma cells compared to delivery of TMZ alone. The 
physical and biological results demonstrate the therapeutic potential of the TMZ-loaded 
peptide hydrogels for local drug delivery in treating GBM. However, further studies using 
in vivo models of GBM are necessary to further confirm the clinical potential of the TMZ-
loaded peptide hydrogels. 
Peptide-based drug delivery shows great promise in the treatment of cancer. 
Drug delivery using peptides can assist in overcoming the blood brain barrier (BBB), and 
in increasing the conversion of pH-activated prodrugs to their active parent drug. The 
peptide hydrogels in this study show potential for becoming a new treatment for GBM. 
With further studies, we aim to optimize this vehicle for delivery of not only TMZ, but 
other anticancer prodrugs. In doing this, we hope to advance therapeutic strategies 
using carriers that enhance drug activity and ultimately increase GBM patient survival 
rates and reduce disease progression.  
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